Alector licenses brain-penetrant Parkinson’s enzyme therapy to Genentech for $100 million upfront

Alector grants Genentech exclusive rights to AL050, a brain-penetrant GCase enzyme therapy for Parkinson’s, for $100 million upfront and up to $1.17 billion more.